Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
- Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B -
- Webcast will be held May 27th, 2026, at 8:00 AM EDT -
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will host an investor webcast to discuss new biopsy and clinical data from the ongoing Phase 1 ELIMINATE-B trial. The presentation will include new clinical data along with late-breaker biopsy data featured at the European Association for the Study of the Liver (EASL) Congress 2026 on May 27, 2026, in Barcelona, Spain. A news release with details of the clinical data will be available here after the conference embargo lifts on May 27, 2026. The ELIMINATE-B trial is evaluating PBGENE-HBV for the treatment of chronic hepatitis B.
The investor webcast will include Company management and Hepatitis B experts and will be held on May 27th, 2026, at 8:00 AM EDT. Pre-registration for the event can be found here.
